Your browser doesn't support javascript.
loading
INR and vitamin K-dependent factor levels after vitamin K antagonist reversal with 4F-PCC or plasma.
Hood, Christopher; Goldstein, Joshua N; Milling, Truman J; Refaai, Majed A; Bajcic, Paolo; Goldstein, Brahm; Sarode, Ravi.
Afiliação
  • Hood C; CSL Behring, King of Prussia, PA.
  • Goldstein JN; Department of Emergency Medicine, Massachusetts General Hospital, Boston, MA.
  • Milling TJ; Department of Neurology, Dell Medical School at the University of Texas, Austin, TX.
  • Refaai MA; Department of Pathology and Laboratory Medicine, Transfusion Medicine Division, Hemostasis and Thrombosis Unit, University of Rochester, Rochester, NY.
  • Bajcic P; CSL Behring, King of Prussia, PA.
  • Goldstein B; CSL Behring, King of Prussia, PA.
  • Sarode R; Departments of Pathology and Internal Medicine, UT Southwestern Medical Center, Dallas, TX.
Blood Adv ; 7(10): 2206-2213, 2023 05 23.
Article em En | MEDLINE | ID: mdl-36574241
Restoration of the international normalized ratio (INR) to values <1.5 is commonly targeted to achieve hemostasis in patients with major bleeding or undergoing urgent surgery who are treated using vitamin K antagonists (VKAs). However, the relationship between corrected INR and vitamin K-dependent factor (VKDF) levels for hemostasis is uncertain. We aim to examine the impact of 4-factor prothrombin complex concentrate (4F-PCC) or plasma on INR correction and VKDF restoration and evaluate the relationship between INR values and VKDF levels in patients with acute major bleeding or patients requiring an urgent surgical procedure. Adult patients treated with VKA with an elevated INR (≥2.0 within 3 hours before study treatment) who received 4F-PCC or plasma after major bleeding or before an urgent surgery or invasive procedure were included in this retrospective analysis of data from 2 prospective phase 3b randomized controlled trials. Of the 370 patients included in this analysis, 185 received 4F-PCC, and 185 received plasma. In the 4F-PCC group, 159 of 185 (85.9%) had an INR ≤1.5 at 30 minutes after the end of infusion compared with only 72 of 184 (39.1%) in the plasma group. After 4F-PCC treatment, all VKDF levels exceeded 50% activity regardless of the postinfusion INR value. However, after plasma administration, mean activity levels for factors II and X were <50% at all time points assessed within 3 hours after starting the infusion, regardless of the postinfusion INR value. This retrospective analysis demonstrated that treatment with 4F-PCC among patients treated with VKA rapidly restores VKDFs to hemostatic levels irrespective of the postinfusion INR value, whereas treatment with plasma does not.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vitamina K / Fator IX Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vitamina K / Fator IX Idioma: En Ano de publicação: 2023 Tipo de documento: Article